Nerviano Medical Sciences S.r.l. Announces BRAFTOVI® Royalty Agreement with Blue Owl Capital, potentially exceeding $80 Million
– NMS to receive in excess of $50 Million in upfront cash and milestone payments; total returns capped at a multiple of investment – Financing proceeds will be used to advance NMS’ current pipeline and ADC platform NERVIANO, Italy and BOSTON, Mass., September 5 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) […]
SIMIS S.r.l. Appoints Marco Dieci as CEO to leverage and expand further opportunities at Nerviano Bio-Park
NERVIANO, IT, September 2, 2024 SIMIS S.r.l. (SIMIS), a part of NMS Group S.p.A. (NMS Group) and a company provides services to the community domiciled in Nerviano Bio-Park, today announced the appointment of Marco Dieci as the new Chief Executive Officer, effective immediately. With an exceptional track record in biotechnology, business development and entrepreneurship, Marco […]
Our scientists to speak at the SCI-2024 – XXVIII National Congress
We are honored to have two senior scientists speaking at the SCI-2024 – XXVIII National Congress in Milan. Elena Ardini: Wednesday, August 28th 8:30am – 9:00am Discovery of entrectinib: an amazing journey from target biology to innovative therapy (KN-028) ParallelTopic04: Health Location: Blue1 (level +1) Barbara Valsasina and Gianfranco Pasut, (Dept. Pharmaceutical and Pharmacological Sciences, University of Padova) […]
Nerviano Medical Sciences announces publication of a research paper in “Chemistry – A European Journal”
Thrilled to announce that our latest paper, in collaboration with Prof. Gian Cesare Tron from Università del Piemonte Orientale (UPO), has just been published in the prestigious “Chemistry – A European Journal”! You can check it out here: link. This publication highlights the strong and productive partnership between our two institutions. By building on the […]
We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA)!
We are speaking at the 3rd GLOBAL XDC INNOVATION CONFERENCE in WuXi (CHINA) partnering event in WuXi (CHINA) , 10 – 12 Sep. 2024 We look forward to your presence to explore future partnership opportunities. * * * * * Contact: Valsasina Barbara : Barbara.Valsasina@demo111.axxiem.com Lupi Rosita: rosita.lupi@demo111.axxiem.com * * * * * About NMS […]
Nerviano Medical Sciences announces FDA protocol clearance of new IND application for NMS-812, a first-in-class dual inhibitor of PERK/GCN2. Brian Sherer, PhD. appointed to lead and accelerate the development.
NMS-812: A clinical phase potent and selective PERK/GCN2 inhibitor, a potential first-in-class targeting the integrated stress response (ISR) The United States Food and Drug Administration (FDA) has cleared the protocol for new investigational new drug (IND) application for NMS-812, a first-in-class orally bioavailable and highly potent small molecule dual inhibitor of PERK/GCN2. NMS […]
Nerviano Medical Sciences announces strategic portfolio shaping.
NERVIANO, IT and BOSTON, Mass, June 21 , 2024 – Nerviano Medical Sciences S.r.l. (“NMS” or the “Company”), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, […]
Nerviano Medical Sciences S.r.l. announced new Board of Directors and Statutory Auditors
NERVIANO, 28, May 2024_Nerviano Medical Sciences S.r.l. (NMS), a wholly owned subsidiary of NMS Group S.p.A, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, announced, following the shareholder resolution dated 13 May 2024, changes to the Board of Directors and Statutory Auditors of the holding company […]
Dr. Frank Narjes Appointed as Head of Medicinal Chemistry and Drug Design, Elevating Innovation at Nerviano Medical Sciences S.r.l.
NERVIANO, IT and BOSTON, Mass, May 13, 2024 – Nerviano Medical Sciences S.r.l. (NMS), a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and development of oncology drugs and the largest oncological R&D company in Italy, welcomes Dr. Narjes to […]
Nerviano Medical Sciences S.r.l. presents data on MPS1 inhibitor NMS-153 and on ADC platform at the AACR annual meeting 2024.
Nerviano Medical Sciences S.r.l. (NMS), a member of NMS Group S.p.A and a clinical stage biotech discovering and developing innovative therapies for the treatment of cancer, is proud of its participation to the American Association of Cancer Research annual meeting (AACR 2024) which took place in San Diego from April 5th to April 10th. NMS […]
